

**LIST OF TABLES**

<b>S.No</b>	<b>Table Number</b>	<b>Title of table</b>	<b>Page number</b>
1.	1.1.	Physical chemical properties used in instrumental methods	02
2.	1.2.	Phase characteristics for separations based on polarity	07
3.	1.3.	Different scales of operation	08
4.	1.4.	Mass analyzers	21
5.	1.5.	Types of precision	30
6.	2.1.	Drugs selected for the work	54
7.	3.4.1.	Optimized chromatographic conditions	67
8.	3.4.2.	Optimized tandem mass spectrometer working parameters	68
9.	3.4.3.	Screening of different batches of blank matrix (Human K <sub>2</sub> EDTA Plasma) for interference free Riluzole blank plasma	76
10.	3.4.4.	Limit of quantitation for analyte (Riluzole)	77
11.	3.4.5.	Specificity of different batches of blank matrix (Human K <sub>2</sub> EDTA Plasma) for Riluzole	78
12.	3.4.6.	Intra batch (Within-Batch) accuracy and precision for determination Riluzole levels in human plasma	79

13.	3.4.7.	Inter batch (Between-Bach) accuracy and precision for determination Riluzole levels in human plasma	80
14.	3.4.8.	Summary of calibration curve parameters for Riluzole in human Plasma	82
15.	3.4.9.	Back-calculated standard concentrations from each calibration curve for Riluzole in human plasma	83
16.	3.4.10.	Recovery of analyte (Riluzole) from human plasma	85
17.	3.4.11.	Recovery of analyte ( $[^{13}\text{C},^{15}\text{N}_2]$ Riluzole) from human plasma	86
18.	3.4.12.	Assessment of matrix effect on determination of Riluzole levels in human plasma	87
19.	3.4.13.	Assessment of matrix effect on determination of IS ( $[^{13}\text{C}, ^{15}\text{N}_2]$ Riluzole) levels in human plasma	88
20.	3.4.14.	Assessment of dilution integrity for Riluzole at DQC Concentration (ng/mL)	89
21.	3.4.15.	Assessment of whole batch re-injection reproducibility during estimation of Riluzole in human plasma	91
22.	3.4.16.	Ruggedness of the method for estimation of Riluzole levels in human plasma with different analyst	92
23.	3.4.17.	Ruggedness of the method for estimation of Riluzole levels in human plasma with different	94

		analytical column	
24.	3.4.18.	Assessment of stability of analyte (Riluzole) in biological matrix at room temperature	96
25.	3.4.19.	Assessment of freeze-thaw stability of analyte (Riluzole) at $-30\pm 5^{\circ}\text{C}$	98
26.	3.4.20.	Assessment of auto sampler stability of analyte (Riluzole) at $2-8^{\circ}\text{C}$	100
27.	3.4.21.	Assessment of long term plasma stability of analyte (Riluzole) at $-30^{\circ}\text{C}$	102
28.	3.4.22.	Assessment of short term stock solution stability of analyte (Riluzole) and internal standard ( $[^{13}\text{C}, ^{15}\text{N}_2]$ Riluzole) at room temperature	104
29.	3.4.23.	Assessment of short term solution stability of internal standard spiking solution ( $[^{13}\text{C}, ^{15}\text{N}_2]$ Riluzole) at room temperature	105
30.	3.5.1.	Optimized chromatographic conditions	112
31.	3.5.2.	Intraday and inter day precision of RLZ	117
32.	3.5.3.	Accuracy of RLZ	118
33.	3.5.4	Assay of RLZ	119
34.	3.5.5.	System suitability parameters	120
35.	3.6.1.	Optimized chromatographic conditions	127
36.	3.6.2.	Linearity of RLZ	133
37.	3.6.3.	Intraday and inter day precision of RLZ	134
38.	3.6.4.	Accuracy of RLZ	135

39.	3.6.5.	System suitability parameters	136
40.	3.6.6.	Robustness of RLZ	137
41.	3.6.7.	Assay of RLZ	138
42.	3.6.8.	Conditions of degradation	141
43.	3.6.9.	Forced degradation recovery of Riluzole hydrochloride	142
44.	4.4.1.	Optimized chromatographic conditions	173
45.	4.4.2.	Concentration Vs Mean peak area of RMT	176
46.	4.4.3.	Statistical data of calibration curves of RMT	177
47.	4.4.4.	Intraday and inter day precision of RMT	178
48.	4.4.5.	Recovery studies of RMT	179
49.	4.4.6.	Assay of RMT	179
50.	4.4.7.	Ruggedness of RMT	180
51.	4.4.8.	Robustness of RMT	181
52.	4.4.9.	System suitability parameters	182
53.	4.5.1.	Optimized chromatographic conditions	188
54.	4.5.2.	Linearity of RMT	191
55.	4.5.3.	Statistical data of calibration curves of RMT	192
56.	4.5.4.	Intraday and inter day precision of RMT	193
57.	4.5.5.	Accuracy of RMT	194
58.	4.5.6.	Assay of RMT	194
59.	4.5.7.	System suitability parameters	195

60.	4.5.8.	Ruggedness of RMT	196
61.	4.5.9.	Robustness of Rimonabant hydrochloride	197
62.	4.6.1.	Optimized chromatographic conditions	205
63.	4.6.2.	Precision of RMT	211
64.	4.6.3.	Accuracy of RMT	212
65.	4.6.4.	System suitability parameters	212
66.	4.6.5.	Assay of RMT	214
67.	4.6.6.	% of Degradation	217
68.	4.6.7.	Forced degradation recovery of RMT	217
69.	5.4.1.	Optimized chromatographic conditions	242
70.	5.4.2.	Linearity of APT	245
71.	5.4.3.	Statistical data of calibration curves of APT	246
72.	5.4.4.	Precision of APT	247
73.	5.4.5.	Accuracy of APT	248
74.	5.4.6.	Assay of APT	248
75.	5.4.7.	System suitability parameters	249
76.	5.4.8.	Ruggedness of APT	250
77.	5.4.9.	Robustness of APT	251
78.	5.5.1.	Optimized chromatographic conditions	258
79.	5.5.2.	Precision of APT	263
80.	5.5.3.	Accuracy of APT	264
81.	5.5.4.	System suitability parameters	265

82.	5.5.5.	Conditions of degradation of APT	267
83.	5.5.6.	Forced degradation recovery of APT	268
84.	6.4.1.	Optimized chromatographic conditions	290
85.	6.4.2.	Concentration Vs mean peak area of ORL	293
86.	6.4.3.	Statistical data of calibration curves of ORL	294
87.	6.4.4.	Precision of ORL	294
88.	6.4.5.	Recovery of ORL	295
89.	6.4.6.	Assay of ORL capsule	296
90.	6.4.7.	System suitability parameters	296
91.	6.4.8.	Ruggedness of ORL	297
92.	6.4.9.	Robustness of the ORL	298
93.	7.4.1.	Optimized chromatographic conditions	315
94.	7.4.2.	Concentration Vs mean peak area of RPR	318
95.	7.4.3.	Statistical data of calibration curves of RPR	319
96.	7.4.4.	Precision of RPR	320
97.	7.4.5.	Recovery studies of RPR	321
98.	7.4.6.	Assay of RPR	321
99.	7.4.7.	System suitability parameters	322
100.	7.4.8.	Ruggedness of RPR	323
101.	7.4.9	Robustness of RPR	324

<b>LIST OF FIGURES</b>
------------------------

S.No	Figure Number	Title of figure	Page number
1.	1.1.	Mechanism of absorption chromatography	06
2.	1.2.	Mechanism of partition chromatography	06
3.	1.3.	Differentiation of mass spectroscopy with other techniques	10
4.	1.4.	Principle of mass spectroscopy	10
5.	1.5.	Schematic of an HPLC instrument	12
6.	1.6.	HPLC pump modules	13
7.	1.7.	A schematic of mass spectrometer	19
8.	1.8.	A schematic of an HPLC/MS instrument	20
9.	1.9.	Bio analytical method development parameters	25
10.	1.10.	Steps involved in bio analytical method development	26
11.	1.11.	Bio analytical validation parameters	39
12.	3.2.1	Chemical structure of Riluzole hydrochloride	58
13.	3.3.1	Infrared spectrum of Riluzole hydrochloride	61
14.	3.3.2.	DSC spectrum of Riluzole hydrochloride	62
15.	3.3.3.	UV absorption spectrum of Riluzole hydrochloride	62
16.	3.4.2.	Riluzole Q <sub>1</sub> scan, [ <sup>13</sup> C, <sup>15</sup> N <sub>2</sub> ]Riluzole Q <sub>1</sub> scan,	66

		Riluzole Q <sub>3</sub> , [ <sup>13</sup> C, <sup>15</sup> N <sub>2</sub> ]Riluzole Q <sub>3</sub> scan	
17.	3.4.3.	MRM chromatogram of blank	70
18.	3.4.4.	Chromatogram of blank human plasma sample	71
19.	3.4.5.	Chromatogram of blank + IS	71
20.	3.4.6	Chromatogram of LOQ sample (Riluzole & IS)	72
21.	3.4.7.	Chromatogram of ULOQ sample ( Riluzole & IS)	72
22.	3.4.8.	Chromatogram of LLOQ sample ( Riluzole & IS)	73
23.	3.4.9.	Chromatogram of LQC sample ( Riluzole & IS)	73
24.	3.4.10.	Chromatogram of MQC sample ( Riluzole & IS)	74
25.	3.4.11.	Chromatogram of HQC sample ( Riluzole & IS)	74
26.	3.4.12.	Calibration curve of RLZ	75
27.	3.5.1	A typical chromatogram of RLZ	114
28.	3.5.2	A typical chromatogram of Rilutek tablets	115
29.	3.5.3	Calibration curve of RLZ	116
30.	3.6.1.	A typical chromatogram of RLZ	128
31.	3.6.2.	A typical chromatogram of RLZ tablets	129
32.	3.6.3.	Calibration curve of RLZ	133
33.	3.6.4.	A chromatogram of acid degraded RLZ at 0 h	143
34.	3.6.5.	A chromatogram of acid degraded RLZ after 6 h	143
35.	3.6.6.	A chromatogram of alkali degraded RLZ at 0 h	144
36.	3.6.7.	A chromatogram of alkali degraded RLZ after 6 h	144



37.	3.6.8.	A chromatogram of degraded RLZ in neutral condition at 0 h	145
38.	3.6.9.	A chromatogram of degraded RLZ in neutral condition after 6 h	145
39.	3.6.10.	A chromatogram of peroxide degraded Riluzole at 0 h	146
40.	3.6.11.	A chromatogram of peroxide degraded Riluzole after 6 h	146
41.	3.6.12.	A chromatogram of thermal degraded bulk drug of RLZ at 0 h	147
42.	3.6.13.	A chromatogram of thermal degraded bulk drug of RLZ after 6 h	147
43.	3.6.14.	A chromatogram of thermal degraded tablet of RLZ at 0 h	148
44.	3.6.15.	A chromatogram of thermal degraded tablet of RLZ after 6 h	148
45.	3.6.16.	A chromatogram of UV degraded RLZ at 0 h	149
46.	3.6.17.	A chromatogram of UV degraded RLZ after 6 h	149
47.	4.2.1.	Chemical structure of RMT	165
48.	4.3.1.	Infra red spectrum of RMT	168
49.	4.3.2.	DSC spectrum of RMT	169
50.	4.3.3.	UV absorption spectrum of RMT	169
51.	4.4.1.	A typical chromatogram of RMT	175
52.	4.4.2.	A typical chromatogram of RMT tablets	175
53.	4.4.3.	Calibration curve of Rimonabant hydrochloride	177
54.	4.5.1	A typical chromatogram of RMT with Saquinavir	190

		mesylate (IS)	
55.	4.5.2.	A typical chromatogram of RMT tablet with Saquinavir mesylate (IS)	190
56.	4.5.3.	Calibration curve of RMT	192
57.	4.6.1.	A typical chromatogram of RMT with Saquinavir mesylate (IS)	208
58.	4.6.2.	A typical chromatogram of RMT tablet with Saquinavir mesylate (IS)	208
59.	4.6.3.	Calibration curve of RMT	210
60.	4.6.4.	A chromatogram of acid degraded RMT at 0 h	218
61.	4.6.5.	A chromatogram of acid degraded RMT after reflux about 12h at 60° C	218
62.	4.6.6.	A chromatogram of alkali degraded RMT at 0 h	219
63.	4.6.7.	A chromatogram of alkali degraded RMT after reflux about 12 h at 60° C	219
64.	4.6.8.	A chromatogram of peroxide degraded RMT at 0 h	220
65.	4.6.9.	A chromatogram of peroxide degraded RMT at 60°C about 8 h	220
66.	4.6.10.	A chromatogram of thermal degraded API of RMT at 70°C about 48h	221
67.	4.6.11.	A chromatogram of thermal degraded tablet of RMT at 70°C about 48 h	221
68.	5.2.1.	Chemical Structure of APT	235
69.	5.3.1.	Infrared spectrum of APT	238
70.	5.3.2.	DSC spectrum of APT	239
71.	5.3.3.	UV absorption spectrum of APT	239

72.	5.4.1.	A typical chromatogram of APT with Rimonabant hydrochloride (IS)	244
73.	5.4.2.	A typical chromatogram of APT capsule with Rimonabant hydrochloride (IS)	244
74.	5.4.3.	Calibration curve of APT	245
75.	5.5.1.	A Standard typical chromatogram of APT with Rimonabant hydrochloride (IS)	260
76.	5.5.2.	A typical chromatogram of APT capsule with Rimonabant hydrochloride (IS)	260
77.	5.5.3.	A chromatogram of acid degraded APT at 0 h	269
78.	5.5.4.	A chromatogram of acid degraded APT after reflux at 60°C about 2h	269
79.	5.5.5.	A chromatogram of alkali degraded APT at 0 h	270
80.	5.5.6.	A chromatogram of alkali degraded APT after reflux at 60°C about 24h	270
81.	5.5.7.	A chromatogram of peroxide degraded APT after reflux at 60°C about 2 h	271
82.	5.5.8.	A chromatogram of thermal degraded API of APT at 70°C about 48 h	271
83.	5.5.9.	A chromatogram of thermal degraded capsule of APT at 70°C about 48 h	272
84.	6.2.1.	Chemical structure of ORL	282
85.	6.3.1	Infrared spectrum of ORL	286
86.	6.3.2.	DSC Spectrum of ORL	287
87.	6.3.3.	UV absorption Spectrum of ORL	287
88.	6.4.1.	A typical chromatogram of ORL	292
89.	6.4.2.	A typical chromatogram of ORL capsule	292

90.	6.4.3.	Calibration curve of ORL	293
91.	7.2.1.	Chemical structure of RPR	307
92.	7.3.1.	Infrared spectrum of RPR	311
93.	7.3.2.	DSC spectrum of RPR	312
94.	7.3.3	UV absorption spectrum of RPR	312
95.	7.4.1	A typical chromatogram of RPR	317
96.	7.4.2	A typical chromatogram of RPR tablets	317
97.	7.4.3.	Calibration curve of RPR	318

<b>LIST OF ABBREVIATIONS</b>
------------------------------

<b>Abbreviated form</b>	<b>Abbreviation</b>
HPLC	High performance liquid chromatography
LC-MS	Liquid chromatography- Mass spectrometry
LOD	Limit of detection
LOQ	Limit of quantification
HQC	High quality control
LQC	Low quality control
FDA	Food and drug administration
ICH	International conference on harmonization
LLOQ	Lower limit of quantification
MQC	Medium quality control
LC/MS/MS	Liquid chromatography/ Mass spectrometry/ Mass spectrometry
RSD	Relative standard deviation
%CV	Coefficient of variation
SD	Standard deviation
DSC	Differential scanning calorimetry
EMR	Electromagnetic radiation
IR	Infra red
UV	Ultra violet

MRM	Multiple reaction monitoring
LLE	Liquid- liquid extraction
SPE	Solid phase extraction
QC	Quality control
USFDA	United states food and drug administration
PDA	Photo diode array detector
HETP	Height equivalent theoretical plate
IS	Internal standard
ESI	Electron spray ionization
RPM	Revolutions per minute
ULOQ	Upper limit of quantification
K <sub>2</sub> EDTA	Di potassium salt of Ethylene di amine tetra acetic acid
TLC	Thin layer chromatography
DP	Declustering potential
EP	Entrance potential
CE	Collision energy
CXP	Collisional cell exit potential
API	Active pharmaceutical ingredient
APCI	Atmospheric pressure chemical ionization
RP-HPLC	Reverse phase- high performance liquid chromatography

PEEK	Poly ether ether ketone
PK	Pharmacokinetic
ELISA	Enzyme linked immune sorbent assay
STP	Standard test procedure
BM	Biological matrix
PL	Plasma
Min.	Minimum
Max.	Maximum
Ltd	Limited
ACN	Acetonitrile